Latest results of the MTA Momentum programme may help overcome drug resistance in cancer cells

The MTA-SE Momentum Molecular Oncology Hematology Research Group at Semmelweis University investigated molecular changes in the therapy of one of the most common types of adult leukemia, chronic lymphocytic leukemia. Researchers have identified a molecular process that plays an important role in the drug resistance of cancer cells. The study was conducted in collaboration with the Research Centre for Molecular Medicine of the Austrian Academy of Sciences (CeMM), the University of Regensburg and the South Pest Hospital.